Mantle Cell Lymphoma
News
Inhibitor may overcome ibrutinib resistance in MCL
The inhibitor, IACS-010759, decreased tumor growth and prolonged survival in mouse models of ibrutinib-resistant lymphoma.
News
RIT consolidation may be an option for unfit MCL patients
Patients who could not undergo transplants had high rates of complete responses to radioimmunotherapy consolidation following induction...
Conference Coverage
Early data support R-BAC for post-BTKi mantle cell lymphoma
GLASGOW – The combination outperformed previously published data for other treatments in the relapsed/refractory setting.
News
MCL survival rates improve with novel agents
Median overall survival for mantle cell patients was between 52 and 57 months in two cancer registries. The researchers pointed to the impact of...
News
Worse survival seen among black patients with MCL
There was a survival gap between black and white patients, even though black patients with mantle cell lymphoma were more likely to be treated in...
News
Bendamustine-rituximab shines in frontline treatment of MCL, iNHL
Long-term follow-up data from the BRIGHT study support bendamustine plus rituximab as a frontline treatment option in mantle cell lymphoma and...
Conference Coverage
Dual-targeted CAR T shows ‘clinical signal’ in NHL
HOUSTON – Due to local manufacturing of the CAR T-cell therapy, most patients were able to receive fresh, rather than cryopreserved, product.
News
Adding palbociclib upped responses in previously treated MCL
The positive response means that the combination of ibrutinib and palbociclib will continue to be tested in a phase 2 trial.
News
Daratumumab disappoints in non-Hodgkin lymphoma trial
The drug, used in multiple myeloma, was safe but ineffective in patients with non-Hodgkin lymphoma.
News
Combo appears to overcome aggressive L-NN-MCL
Two case studies highlight the role that P53 gene status plays in prognosis and treatment.